Abstract 170P
Background
The synergic combination of anti-PD-1/PD-L1 and antiangiogenic agents has exhibited as an encourage treatment pattern in aHCC. Multi-targeted antiangiogenic TKIs, such as lenvatinib and sorafenib, are approved for 1st-line treatment of aHCC. Sintilimab, a novel selective anti-PD-1 monoclonal antibody, has demonstrated encouraging clinical activities in aHCC. The trial aims to explore the safety and efficacy of sintilimab plus anlotinib (a TKI against angiogenesis) in aHCC.
Methods
This is a single-arm phase II study. Pts with aHCC, BCLC stage C or B (not amenable for surgery and chemoembolization), Child-Pugh scores≤7 and ECOG PS ≤ 1 received 1st-line treatment of sintilimab (200mg, iv, D1) plus anlotinib (12mg, po, QD, D1-14) every 3 wks until disease progression or unacceptable toxicity. Primary endpoints were safety and objective response rate (ORR, per RECIST 1.1), and secondary endpoints included disease control rate (DCR), progression free survival (PFS), duration of response (DOR) and overall survival (OS).
Results
As of June 30, 2020, 16 pts with 14 males, median age 56 yrs (range 41-70), BCLC B /C (3/13), and Child-Pugh A/B7(15/1) were enrolled. All pts received at least two cycles of treatments with median cycles 7 (range 2-18). Median follow-up was 5.3 months (range 2.1-13.3). The most common treatment-related adverse events (TRAEs) were grade 1-2 with thrombocytopenia (50%), increased AST (37.5%), ALT (31.3%) and bilirubin (31.3%), decreased neutrophil count (31.3%), leukopenia (25%), hypertension (25%) and hand-foot syndrome (25%). 6 pts experienced manageable grade 3 TRAEs, and no grade 4/5. 7 pts required dose reduction of anlotinib (4 pts to 10 mg and 3 to 8 mg). No treatment withdraw caused by TRAEs. Of 14 evaluable pts, ORR was 42.9% (6/14) with 1 CR and 5 PR. 7 pts were SD, and DCR was 92.9% (13/14). Median DoR was not reached (95%CI: 9.0 months-not reached), and all the responses were ongoing at the data cutoff. 6m-PFS rate was 78.8% (95%CI: 38.1%-94.3%) and mPFS was unreached.
Conclusions
The combination of sintilimab and anlotinib showed promising clinical activities with manageable toxicity for first line treatment of aHCC. Enrolment is on-going to further validate the combination regimen.
Clinical trial identification
NCT04052152.
Editorial acknowledgement
Legal entity responsible for the study
Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University.
Funding
Jiangsu province 333 high level Talents Project; Innovation Funds from Chinese Society of Clinical Oncology Youth Committee. Y-young2019-060; the Advanced Health Talent of Six-One Project of Jiangsu Province. LGY2017069; Joint Research Project by Southeast University and Nanjing Medical University. 3207027381; National Natural Science Foundation of China, 81472306; Key research and development program of Jiangsu Province.BE2016789.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session